[go: up one dir, main page]

AU7108400A - Modulation of gene expression by modulating histone acetylation - Google Patents

Modulation of gene expression by modulating histone acetylation

Info

Publication number
AU7108400A
AU7108400A AU71084/00A AU7108400A AU7108400A AU 7108400 A AU7108400 A AU 7108400A AU 71084/00 A AU71084/00 A AU 71084/00A AU 7108400 A AU7108400 A AU 7108400A AU 7108400 A AU7108400 A AU 7108400A
Authority
AU
Australia
Prior art keywords
modulation
gene expression
histone acetylation
modulating histone
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71084/00A
Inventor
Marc R. Montminy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of AU7108400A publication Critical patent/AU7108400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU71084/00A 1999-09-03 2000-09-01 Modulation of gene expression by modulating histone acetylation Abandoned AU7108400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39051699A 1999-09-03 1999-09-03
US09390516 1999-09-03
PCT/US2000/024211 WO2001017514A1 (en) 1999-09-03 2000-09-01 Modulation of gene expression by modulating histone acetylation

Publications (1)

Publication Number Publication Date
AU7108400A true AU7108400A (en) 2001-04-10

Family

ID=23542779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71084/00A Abandoned AU7108400A (en) 1999-09-03 2000-09-01 Modulation of gene expression by modulating histone acetylation

Country Status (2)

Country Link
AU (1) AU7108400A (en)
WO (1) WO2001017514A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20050009030A1 (en) * 2002-03-26 2005-01-13 Fabien Schweighoffer Histone deacetylase: novel molecular target of neurotoxicity
FR2837838B1 (en) * 2002-03-26 2005-01-28 Exonhit Therapeutics Sa NOVEL MOLECULAR TARGET FOR NEUROTOXICITY
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8946295B2 (en) 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8163764B2 (en) 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8883148B2 (en) 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (en) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 Histone deacetylase inhibitors
ES2299284B1 (en) * 2004-11-04 2009-04-16 Universidad Pablo De Olavide CONTROL OF GENE EXPRESSION THROUGH THE USE OF A TRANSCRIPTION ATTENATOR.
JP2008524246A (en) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0775593A (en) * 1993-09-08 1995-03-20 Suntory Ltd Production of protein
US5710176A (en) * 1994-09-16 1998-01-20 Bar-Ilan University Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US5972608A (en) * 1997-08-27 1999-10-26 University Of Massachusetts Assays and reagents for chromatin remodeling enzymes and their modulators

Also Published As

Publication number Publication date
WO2001017514A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU7108400A (en) Modulation of gene expression by modulating histone acetylation
AU3561700A (en) Correction of dc-offset of i/q modulator
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU6647700A (en) Antisense modulation of human rho family gene expression
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU5444300A (en) Antisense modulation of b7 protein expression
AU3659799A (en) Antisense modulation of cd40 expression
AU5009200A (en) Novel beta-secretase and modulation of beta-secretase activity
AU3561900A (en) Correction of nonlinearity of i/q modulator
AU1245001A (en) Antisense modulation of nucleolin expression
AU6115400A (en) Antisense modulation of mekk5 expression
AU7876900A (en) Antisense modulation of fra-1 expression
AU6109200A (en) Antisense modulation of shp-2 expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU2708500A (en) Antisense modulation of cd44 expression
AU2213600A (en) Antisense modulation of mdmx expression
AU4187200A (en) The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AU1920600A (en) Antisense modulation of phospholipase a2 group iv expression
AU2002225915A1 (en) Antisense modulation of histone deacetylase 1 expression
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU2002213431A1 (en) Modulation of gene expression using localization domains

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase